This medical technology company supplies single-use devices for critical care and surgery to hospitals and healthcare providers worldwide.

Teleflex’s TFX Interventional Urology portfolio is well positioned for sustained growth, led by UroLift’s expanding global footprint and strong clinical differentiation. Supported by favorable ...

Teleflex's TFX robust performance in the Interventional product line is poised to help it grow in the upcoming quarters. The Urolift system is seeing consistent growth in hospitals, with positive ...

The stock's fall snapped a four-day winning streak.

What recent performance says about Teleflex Teleflex (TFX) has drawn attention after a mixed stretch, with the stock up about ...

Teleflex (NYSE:TFX) is slated for expansion in the coming quarters, owing to the key growth drivers in the Interventional business. The company's market dominance in Central Venous Catheters and ...

Teleflex (NYSE:TFX – Free Report) had its price objective lowered by Mizuho from $150.00 to $130.00 in a research report released on Wednesday,Benzinga reports. The brokerage currently has a neutral ...

On August 1, Teleflex will release earnings for the most recent quarter. Analysts on Wall Street expect Teleflex will release earnings per share of $3.33. Track Teleflex stock price in real-time on ...

Teleflex Incorporated, a diversified medical device company, saw a 17% stock drop after Q3 results in late October. The stock now trades at under 13.5 EPS (non-GAAP) and at the equity's lowest ...

This was the stock's second consecutive day of losses.